Summit Therapeutics Inc. SMMT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -832.68M | -856.09M | -1.21B | -1.08B | -921.62M |
| Total Depreciation and Amortization | 217.00K | 174.00K | 165.00K | 146.00K | 126.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 287.15M | 374.20M | 785.95M | 725.09M | 629.43M |
| Change in Net Operating Assets | 20.15M | 23.29M | 35.93M | 31.42M | 22.39M |
| Cash from Operations | -525.17M | -458.43M | -384.05M | -322.93M | -269.67M |
| Capital Expenditure | -1.71M | -1.39M | -480.00K | -657.00K | -507.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -464.95M | -261.18M | -334.18M | -173.65M | 394.84M |
| Cash from Investing | -466.66M | -262.57M | -334.66M | -174.31M | 394.33M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -24.50M |
| Issuance of Common Stock | 904.13M | 842.51M | 613.65M | 617.53M | 44.60M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 904.13M | 842.51M | 613.65M | 617.53M | 20.10M |
| Foreign Exchange rate Adjustments | -46.00K | -15.00K | 45.00K | 102.00K | 13.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -87.75M | 121.49M | -105.01M | 120.40M | 144.78M |